Skip to main content
. 2012 Jul 18;32(29):9773–9784. doi: 10.1523/JNEUROSCI.0354-12.2012

Figure 8.

Figure 8.

A, Representative sections immunostained with an anti-NFT (phospho-tau) antibody show that PTI-125 treatment dramatically reduced NFT immunoreactivity in both prefrontal cortex and hippocampus of mice receiving ICV Aβ42 infusions. B, Representative sections immunostained for Aβ42 aggregates show that PTI-125 treatment greatly reduced Aβ42 deposits in both brain regions of Aβ42-infused mice. Immunostaining was quantified by image analysis software. n = 7 or 8. *p < 0.01 vs sham, vehicle; #p < 0.01 vs Aβ42, vehicle.